Member Info for Matml74

Andy, Prior to covid the drug was developed to treat hospitalialised asthma/copd patients when they present with a viral lung infection. Obviously people with these conditions are more likely to end up in hospital with severe symptoms and this is where sng001 comes into use.

It’s not used to treat the other chronic symptoms of asthma/copd.

The usefulness of this drug with long covid (hopefully) will be in stopping covid infections quickly and therefore reducing the number of people ending up with long covid.

There are so many nuggets in those job adverts..... I like this one with respect to the Alliance management position...... “and expanding relationships with key vendors supporting our US/global launch, initially prioritizing device manufacturing partner to ensure supply”

WF, Agree totally with your thoughts. Free float is considerably less than shares in issue, around 40% I think from rough calculations. I will say that it will be important to have movable targets if planning on top slicing and adjusting these on the content of any positive rns. Being able to actually understand what the data means and how that could relate to future orders and MCAP will be important in setting targets to sell at.

From November 21 but only online now in Journal in Microbiology......

“We discuss key questions surrounding how such autoantibodies develop and function, as well as the general implications of diagnosing interferon deficiencies for personalized therapies.”

"Regardless, the continued identification of new interferon-system-related genetic traits, or anti-interferon antibody profiles, that predispose individuals to severe virus infections could form the basis of new personalized medicine strategies to prioritize at-risk individuals for preventative measures (such as vaccination) or appropriate treatments. For example, plasma exchange has already been trialled to remove anti-interferon autoantibodies from the blood of patients with life-threatening COVID-19 [46], and recombinant interferon-ß or interferon-? could provide a life-saving boost to innate antiviral defenses in individuals with autoantibodies that neutralize interferon-a and interferon-? [12], mirroring a successful interferon-based strategy to treat severe COVID-19 patients with genetic deficiencies in interferon production"

https://www.sciencedirect.com/science/article/pii/S0966842X21000603

Agree totally Ghia.

Wigster, What happens in the UK on Monday with respect to Boris is irrelevant IMO. The good ol' US of A is where this drug will be heading. It's what the new website, recruitment and the words in all the recent rns's have indicated. As Doc says. This news will be global. The PR machine will focus on the US media. Front page of the NY times will mean more than any mention on the BBC or UK media.

I don’t know why anyone is even responding to the troll. We have been through this with him before but he hasn’t even read the protocol. There is a 25% contingency in the trial numbers and it would still have 90% power.

Move on or filter. Just clogs the board up with crap.

No its still wrong as you are assuming that the only variable having and effect on progressing to severe disease is the treatment without taking into account any differences in the participants within each group (comorbidities, baseline OCSI, etc etc). Statistics, and in this case a logistic regression model, takes into account these other variables.

In the P2 a larger proportion of the the treatment group started with more severe disease than the placebo group (72% vs 58% from memory) and so the odds ratio takes things like this into account and provides a better measure than the absolute percentage you applied to the data.

You are not interpreting the results correctly. The results are presented as odds/hazard ratios. This is how most clinical trials looking to show a beneficial effect of one treatment over another are presented.

The results state ..... "SNG001 reduced the odds of developing severe disease or dying by 79% SNG001 reduced the odds of developing severe disease or dying by 79% (OR 0·21 [95% CI 0·04–0·97]; p=0·046) in the prespecified logistic regression analysis. As quasi-complete separation of data was observed in some model covariates, an additional, post-hoc Firth logistic regression analysis was done in which the difference between groups was not significant (72·0% reduction; OR 0·28 [95% CI 0·07–1·08]; p=0·064; table 3)."

Odds ratio of 0.21 means there is an 79% decrease in the odds of an outcome with a given exposure. In this case outcome is "severe disease' and exposure is "treatment with SNG001".

You will also note hazard ratios for time to recovery one of the primary endpoints in the P3 below....

" Over the 14-day treatment period, patients in the SNG001 group were more than twice as likely to recover as those in the placebo group (21 [44%] of 48 with SNG001 vs 11 [22%] of 49 with placebo; hazard ratio [HR] 2·19 [95% CI 1·03–4·69]; p=0·043; table 3; figure 3). On day 28 (the final outcome assessment visit), 28 (58%) of 48 patients in the SNG001 group and 17 (35%) of 49 in the placebo group had recovered (figure 3; appendix p 5). The odds of recovery on day 28 were more than three-fold greater in the SNG001 group than in the placebo group (OR 3·58 [95% CI 1·41–9·04]; p=0·007; figure 2)."

Threshold is 3% CR

CPMOD,

On the 20th July the SP opened at a pound and was up over £2 during the day. I expect they started buying that day not prior to P2 readout. They did buy a few percent on the vaccine drop to 80p but most of their holding they accumulated over £1.

Sprinter.

It will be more than enough for EUA. There are basically no effective hospital treatment available and the US is in dire need of them.

Firstly the results aren't delayed. There have been 20 working days since unblinding.

Of curse the jobs relate to P3. If you read the rns you will know the US is where they will be applying for EUA.

Ronny,

A few points.

At the time of the RNS for Activ-2 SNG might not received any data but it is certainly written into the Activ-2 protocol that the data would be shared with a small team at the company so this may have happened at a later date.

Secondly and most people won't realise this if they had not read the SG018 protocol is that for quality assurance there is the following statement...... "In order to verify that the study is conducted in accordance with the study protocol, ICH GCP, local regulatory requirements and other applicable guidelines, data will be monitored at regular intervals. This will allow the sponsor to ensure that the data is authentic, accurate and complete."

So whilst who was on placebo/drug was 'blinded' the actual data that was being received was continually being checked for quality control. IMO the company would/should have had someone modelling the data coming in regularly throughout the trial and by making assumptions based on their previous datasets would be able to have some idea if positive data was likely. This could then be easily checked once the data was unblinded mid December and the ball start rolling in terms of scaling up the company readout for readout.

This combined with the futility analysis at the midpoint of the trial allowed the company to engage with companies like Ashfeild. We know that this was happening in the summer as it was reported on in the September interims.

So IMO the new website and some of the terminology within it "breakthrough" etc plus the range of jobs advertised is a very strong indication of where this is going rather than just based on 'hope" as you put it.

Says it all Scott!

Nope. Progression in Activ-2 came out in a Wednesday.

Congrats BC. Enjoy every moment. They grow up to fast!

Brand, They hadn't when I checked yesterday.

Mattw007,

"On confirmation, they need it to take you to a page which says something like: "Thanks, you have now been registered to receive the alerts... blah, blah"

I got this message on a new window.....

"Thank you. Your subscription process has been completed successfully.

You can continue browsing."

Sorry Laim. Saw you are collating. Great work!

Matterhorn, Brooke has been responding to messages quickly about spelling errors etc on the new site. It is worth emailing her if you haven't done so already about the performance page issue.